Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.

Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE.

J Immunol. 2019 Aug 21. pii: ji1900696. doi: 10.4049/jimmunol.1900696. [Epub ahead of print]

PMID:
31434709
2.

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.

Polesso F, Weinberg AD, Moran AE.

Cancer Immunol Res. 2019 Feb;7(2):269-281. doi: 10.1158/2326-6066.CIR-18-0222. Epub 2018 Dec 18.

PMID:
30563828
3.

Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production.

Polesso F, Sarker M, Anderson A, Parker DC, Murray SE.

Sci Rep. 2017 Nov 7;7(1):14779. doi: 10.1038/s41598-017-14965-x.

4.

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Moran AE, Polesso F, Weinberg AD.

J Immunol. 2016 Sep 15;197(6):2509-21. doi: 10.4049/jimmunol.1502659. Epub 2016 Aug 8.

5.

NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice.

Murray SE, Polesso F, Rowe AM, Basak S, Koguchi Y, Toren KG, Hoffmann A, Parker DC.

J Clin Invest. 2011 Dec;121(12):4775-86. doi: 10.1172/JCI44943.

6.

Chd1 regulates open chromatin and pluripotency of embryonic stem cells.

Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A, Ramalho-Santos J, McManus MT, Plath K, Meshorer E, Ramalho-Santos M.

Nature. 2009 Aug 13;460(7257):863-8. doi: 10.1038/nature08212. Epub 2009 Jul 8.

7.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H.

Neoplasia. 2008 Apr;10(4):340-7.

Supplemental Content

Loading ...
Support Center